


Arteris

3Q 2026 Earnings Presentation

Charlie Janac
CEO

Saurabh Sinha
CFO

November 5, 2026

ARTERIS IP

© 2026 Arteris, Inc.

Disclaimer

This presentation and the accompanying oral presentation have been prepared by Arteris, Inc. ("Arteris“ or “the "Company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or Arteris or any officer, director, employee, agent or advisor of Arteris. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. Information provided in this presentation and the accompanying oral presentation speak only as of the date hereof.

This presentation and the accompanying oral presentation include express and implied "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "project," "will," "would," "should," "could," "can," "predict," "potential," "target," "explore," "continue," or the negative of these terms, and similar expressions intended to identify forward-looking statements. However, not all forward-looking statements contain these identifying words. These statements may relate to our market size and growth strategy, our estimated and projected costs, margins, revenue, expenditures and growth rates (including our 4th quarter and 2026 full year guidance), our future results of operations or financial condition, our plans and objectives for future operations, growth, initiatives, or strategies. By their nature, these statements are subject to numerous uncertainties and risks, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. These assumptions , uncertainties and risks include, among others, risks related to: market conditions and global economic factors, our ability to access debt and equity financing, our efforts to establish and maintain proper and effective internal controls, and other factors relating to our business, operations and financial performance. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results or outcomes to differ materially from those contained in any forward-looking statements we may make. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur. Moreover, neither we, nor any other person, assumes responsibility for the accuracy and completeness of these statements. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. Except to the extent required by federal securities laws, we undertake no obligation to update any information or any forward-looking statements as a result of new information, subsequent events, or any other circumstances after the date hereof, or to reflect the occurrence of unanticipated events.

This presentation and the accompanying oral presentation also contain estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we compete are necessarily subject to a high degree of uncertainty and risk.

In addition to the financials presented in accordance with U.S. generally accepted accounting principles ("GAAP"), this presentation includes the following non-GAAP metrics: non-GAAP operating expenses, non-GAAP operating income (loss) and free cash flow. Non-GAAP metrics have limitations as analytical tools and you should not consider them in isolation or as a substitute for or superior to the most directly comparable financial measures prepared in accordance with U.S. GAAP. There are a number of limitations related to the use of non-GAAP metrics versus their nearest GAAP equivalents. Other companies, including companies in our industry, may calculate non-GAAP metrics differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP metrics as tools for comparison. We urge you to review the reconciliation Arteris' non-GAAP metrics to the most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business. See the Appendix for reconciliation between each non-GAAP metric and the most comparable GAAP measure.

Arteris is unable to provide a reconciliation of certain non-GAAP guidance metrics in this presentation because the corresponding GAAP measures are not accessible on a forward-looking basis. Due to the potential variability and limited visibility of the excluded items, providing such reconciliation would necessitate unreasonable effort.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

© 2026 Arteris, Inc.

3Q Business Highlights

- Met or exceeded the top-end of all guided metrics. ACV+Royalties of $104 million, a 39% Y/Y increase, as well as record revenue, royalties, and RPO backlog
- Strong license activity in the quarter supported by integration of data center, edge, and physical AI computing across all market verticals. Increase in customers shifting to multi-product orders, supporting the ever-growing complexity of semiconductor innovation;
- Surpassed 1,000 customer confirmed design starts since inception. Arteris has supported innovation from the smartphone inflection to today's deployments in sophisticated infrastructure AI, intelligent edge devices, and physical AI;
- Expanded our chiplet and multi-die solution. FlexGen Multi-Die and Ncore Multi-Die products support chiplet architectures for agentic AI workflows, HPC, data center, cloud infrastructure, physical AI, and more

© 2026 Arteris, Inc.

Key Arteris Customer and Ecosystem Highlights from Last Quarter


Expanding adoption across cloud, AI compute, automotive and trusted silicon.



HYPERSCALE

A leading hyperscaler expands its Arteris license

Extending adoption to HPC chips and chiplets.



AI COMPUTE

Two leading semiconductor companies deepen adoption

Expanded use of Arteris supports next-generation AI accelerators and data center compute.



AUTOMOTIVE

A major OEM advances successive chip generations

Arteris technology supports the OEM's in-house advanced chip designs.



CYBERSECURITY

Cycuity expands its trusted third-party IP program

Third-party IP program through the Trusted and Assured Microelectronics program, in collaboration with BAE Systems and SiFive.

BROADENING ADOPTION OF TRUSTED SYSTEM IP AND HARDWARE SECURITY ASSURANCE ACROSS THE SILICON ECOSYSTEM

© 2026 Arteris, Inc.

3Q 2026 Results

Revenue, ACV + Royalties, RPO, NG Gross Profit

	3Q 2025	2Q 2026	3Q 2026 Guidance	3Q 2026
Revenue	$17.4M	$24.1M	$24M - $25M	**$25.8M** *(+48% Y/Y)*
ACV + Royalties	$74.9M	$99.5M	$99M - $103M	**$104M** *(+39% Y/Y)*
RPO	$105M	$135M	N/A	**$135M** *(+29% Y/Y)*
Gross Profit*	**Non-GAAP:** $15.9M (91%)	**Non-GAAP:** $21.0M (87%)	N/A	**Non-GAAP:** **$22.8M** (89%)

**Non-GAAP measure: See appendix for reconciliation to closest GAAP measure*

© 2026 Arteris, Inc.

3Q 2026 Results

Operating Expenses, Operating Income (Loss)

	3Q 2025	2Q 2026	3Q 2026 Guidance	3Q 2026
Operating Expenses	**Non-GAAP*: $19.5M** GAAP: $24.4M	**Non-GAAP*: $25.5M** GAAP: $34.4M	N/A	**Non-GAAP*: $24.0M** *(+24% Y/Y)* GAAP: $33.6M
Operating Income (Loss)	**Non-GAAP*: ($3.5M)** GAAP: ($8.7M)	**Non-GAAP*: ($4.6M)** GAAP: ($13.9M)	**Non-GAAP*:** **($1M) – ($3M)**	**Non-GAAP*: ($1.2M)** *(+65% Y/Y)* GAAP: ($11.3M)

**Non-GAAP measure: See appendix for reconciliation to closest GAAP measure.*

© 2026 Arteris, Inc.

3Q 2026 Results

Free Cash Flow, Cash

	3Q 2025	2Q 2026	3Q 2026 Guidance	3Q 2026
Free Cash Flow*	$2.5M	$8.6M	Not provided	**($2.1M)**
Cash, Cash Equivalents & Investments	$56.2M	$123M	N/A	**$120M**

**Non-GAAP measure: See appendix for reconciliation to closest GAAP measure*

© 2026 Arteris, Inc.

Guidance

4Q 2026 Guidance

ACV + Royalties[1]

$103M - $107M

Revenue[2]

$25.7M - $26.7M

Non-GAAP Op. Income

($0.9M) – $1.1M

FY 2026 Guidance

ACV + Royalties[3]

$103M - $107M
(+$1M from previous guidance)

Revenue[4]

$98.5M - $99.5M
(+$2.5M from previous guide)

Non-GAAP Op. Income

($9.2M) – ($7.2M)
(+$0.3M from previous guide)

Free Cash Flow

$5M – $9M
(maintained)

1. *105M at the midpoint, +$21.4M Y/Y (+26%)*
2. *26.2M at the midpoint, +$6.1M Y/Y (+30%)*
3. *105M at the midpoint, +$21.4M Y/Y (+26%)*
4. *99M at the midpoint, +$28.4M Y/Y (+40%)*

Arteris has not provided a quantitative reconciliation of its 4Q 2026 or FY 2026 guidance for non-GAAP operating income or free cash flow, in either case, to the closest GAAP measure, within this press release because the Company is unable, without making unreasonable efforts, to calculate certain reconciling items with confidence. These items, which could materially affect the computation of forward-looking GAAP measures, are inherently uncertain and depend on various factors, some of which are outside of the Company's control.

© 2026 Arteris, Inc.

Appendix - Non-GAAP Financial Measures

To supplement our financial results, which are prepared and presented in accordance with GAAP, we use certain non-GAAP financial measures, as described below, to understand and evaluate our core performance. These non-GAAP measures, which may be different than similarly-titled measures used by other companies, are presented to enhance investors' overall understanding of our financial performance and should not be considered in isolation, as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

We define "Non-GAAP gross profit" and "Non-GAAP gross margin" as GAAP gross profit and GAAP gross margin, respectively, adjusted for stock-based compensation expense included in cost of revenue and amortization of acquired intangible assets included in cost of revenue. We define "Non-GAAP loss from operations" as our GAAP loss from operations adjusted to exclude stock-based compensation expense, amortization of acquired intangible assets and acquisition-related costs, which include advisory, legal, accounting, valuation, other professional or consulting fees, integration costs and changes in the fair value of the contingent consideration related to our acquisition of Cycuity. We define "Non-GAAP net loss" as our net loss adjusted to exclude stock-based compensation, amortization of acquired intangible assets and acquisition-related costs.

The above items are excluded from our Non-GAAP gross profit, Non-GAAP operating expenses and Non-GAAP operating income (loss) because these items are non-cash in nature, or are not indicative of our core operating performance, and render comparisons with prior periods and competitors less meaningful. We believe Non-GAAP gross profit, Non-GAAP operating expenses and Non-GAAP operating income (loss) provide useful supplemental information to investors and others in understanding and evaluating our results of operations, as well as provide a useful measure for period-to-period comparisons of our business performance.

We define free cash flow as net cash provided by (used in) operating activities less cash used for purchases of property and equipment. We believe that free cash flow is a useful indicator of liquidity that provides information to management and investors, even if negative, about the amount of cash used in our operations other than that used for investments in property and equipment.

© 2026 Arteris, Inc.

Appendix - GAAP To Non-GAAP Reconciliation

Gross profit

In $ thousands	Three Months Ending: Sep 30, 2025	June 30, 2026	Sep 30, 2026
Revenue	17,408	24,134	25,774
Gross profit	15,642	20,527	22,323
Add:			
Stock-based compensation expense included in cost of revenue	228	384	442
Amortization of acquired intangible assets	50	50	50
Non-GAAP gross profit	15,920	20,961	22,815
Non-GAAP gross margin	91%	87%	89%

© 2026 Arteris, Inc.

Appendix - GAAP To Non-GAAP Reconciliation

Operating expenses

In $ thousands	Three Months Ending: Sep 30, 2025	June 30, 2026	Sep 30, 2026
Operating expenses	24,356	34,435	33,639
Less:			
Stock-based compensation expense	4,728	5,963	8,744
Amortization of acquired intangible assets	167	727	726
Acquisition-related costs	-	2,215	121
Non-GAAP operating expenses	19,461	25,530	24,048

© 2026 Arteris, Inc.

Appendix - GAAP To Non-GAAP Reconciliation

Operating income (loss)

In $ thousands	Three Months Ending: Sep 30, 2025	June 30, 2026	Sep 30, 2026
Operating Income (Loss)	(8,714)	(13,908)	(11,316)
Add:			
Stock-based compensation expense	4,956	6,347	9,186
Amortization of acquired intangible assets	217	777	776
Acquisition-related costs	-	2,215	121
Non-GAAP Operating Income (Loss)	(3,541)	(4,569)	(1,233)

© 2026 Arteris, Inc.

Appendix –Free Cash Flow

In $ thousands	Three Months Ending: Sep 30, 2025	June 30, 2026	Sep 30, 2026
Net cash provided by (used in) operating activities	3,187	9,210	(1,751)
Less:			
Purchase of property and equipment	716	595	375
Free cash flow	2,471	8,615	(2,126)

© 2026 Arteris, Inc.